In another study involving 7187 patients across 21 cancer types, 36 variables associated with anti-PD-1/PD-L1 therapy response were systematically assessed, and the top three most predictive response factors were identified, including CD8+ T-cell abundance (Spearman R = 0.72; p < 2.3 × 10–4), TMB (Spearman R = 0.68; p < 6.2 × 10–4), and the fraction of samples with high PD-1 gene expression (Spearman R = 0.68; p < 6.9 × 10–4) [121]. The gene discussed is PDCD1; the disease is cancer.